- Pressemitteilung BoxID 70283
Capsulution Expands its Developmental Facilities
New projects on anti-cancer substances
The aim is to develop Nanotechnology-based delivery systems for cytotoxic substances, like they are employed in modern cancer therapy. Such active compounds require both special laboratory and occupational health and safety conditions. Therefore, a high development quality and safety standard will be secured by a new, separate working area at Capsulution.
The new laboratory equipment will also be employed for example within the framework of cooperation with AcriTec AG and Schering AG, as was announced in March. According to this cooperation, the companies will concentrate on the development of special hydro-gels that on the one hand have the quality for best possible usage and transport and on the other hand are capable for the controlled release of embedded nanoparticles. These nanoparticles contain active substances and the release of them can take place via a controlled time frame. The combination of functional hytro-gels and embedded nanoparticles enables a targeted release of active substances, which reduces the dosage frequency of the application and increases the therapy safety.
“The extension of the laboratory technology is a vital key to success for our customers and staff alike and at the same time motivates us to further our product development more effectively under the most modern conditions,” states Lutz Kröhne, project director at Capsulution. The handling of highly effective new active components (NCEs) will soon be possible too with the help of our new laboratory technology.
About Capsulution Pharma AG
Capsulution NanoScience AG is a leading nanotechnology company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on tunable nano-sized capsules. The company implements its worldwide-patented LBL Technology®. Based on their minute size, their functionality and their highly reproducible production process, the tunable capsules can be used in a multitude of different applications. Accordingly, the precision-sized capsules can be made to function in a manner suited to the intended application, and can be given biochemical, electrical, optical and magnetic properties tailored to the individual customer. In order to meet customers’ needs for complete product solutions, Capsulution designated EBARA Corp. as the preferred developer, manufacturer and distributor for automated LBL units. In 2005, the renowned growth consultants Frost & Sullivan awarded the year’s “Product Differentiation Innovation Award” in the global nanobiotechnology market to Capsulution NanoScience AG, Berlin. The company received the award for the innovative and diverse use of their proprietary nanobiotechnology product platform, which can be implemented in various life sciences applications.
Weitere Pressemitteilungen dieses Herausgebers
- 22.02.2010 - Into the future with a stronger team
- 17.11.2008 - Capsulution and NanoDel merge their businesses
- 17.11.2008 - Capsulution und NanoDel schließen sich zu Capsulution Pharma zusammen